Moody Aldrich Partners LLC Buys New Shares in Scholar Rock Holding Co. (NASDAQ:SRRK)

Moody Aldrich Partners LLC purchased a new stake in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 27,786 shares of the company's stock, valued at approximately $1,201,000.

Several other hedge funds have also added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. raised its stake in Scholar Rock by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,895 shares of the company's stock worth $25,000 after purchasing an additional 514 shares in the last quarter. GAMMA Investing LLC grew its position in Scholar Rock by 51.8% during the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company's stock worth $34,000 after buying an additional 269 shares in the last quarter. Quarry LP increased its stake in Scholar Rock by 3,443.3% during the 3rd quarter. Quarry LP now owns 4,500 shares of the company's stock worth $36,000 after acquiring an additional 4,373 shares during the period. Nisa Investment Advisors LLC raised its holdings in Scholar Rock by 1,321.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock valued at $48,000 after acquiring an additional 1,031 shares in the last quarter. Finally, Hsbc Holdings PLC acquired a new stake in shares of Scholar Rock during the 2nd quarter worth $100,000. Institutional investors and hedge funds own 91.08% of the company's stock.

Insiders Place Their Bets

In other Scholar Rock news, insider Jing L. Marantz sold 5,655 shares of the stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $44.20, for a total transaction of $249,951.00. Following the transaction, the insider now directly owns 67,200 shares in the company, valued at $2,970,240. This represents a 7.76 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Public Equities L.P. Invus sold 409,433 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $38.49, for a total transaction of $15,759,076.17. Following the transaction, the insider now owns 10,850,005 shares in the company, valued at approximately $417,616,692.45. This represents a 3.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 458,974 shares of company stock valued at $17,948,788 over the last 90 days. Insiders own 19.20% of the company's stock.

Scholar Rock Trading Down 5.1 %

SRRK traded down $2.16 during trading on Thursday, reaching $40.40. The company had a trading volume of 870,396 shares, compared to its average volume of 992,263. Scholar Rock Holding Co. has a 52 week low of $6.76 and a 52 week high of $46.98. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. The business has a 50 day simple moving average of $41.94 and a 200-day simple moving average of $24.97. The stock has a market cap of $3.78 billion, a P/E ratio of -17.19 and a beta of 0.52.

Analyst Ratings Changes

SRRK has been the subject of several analyst reports. Truist Financial boosted their target price on shares of Scholar Rock from $36.00 to $45.00 and gave the company a "buy" rating in a research report on Monday, November 25th. Wedbush reaffirmed an "outperform" rating and set a $47.00 target price on shares of Scholar Rock in a research report on Wednesday. JPMorgan Chase & Co. lifted their target price on shares of Scholar Rock from $18.00 to $31.00 and gave the stock an "overweight" rating in a research note on Monday, October 14th. BMO Capital Markets increased their price target on Scholar Rock from $34.00 to $38.00 and gave the stock an "outperform" rating in a report on Friday, October 11th. Finally, Piper Sandler increased their price target on Scholar Rock from $28.00 to $42.00 and gave the stock an "overweight" rating in a report on Tuesday, October 15th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $40.43.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.